Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 37

References for PMC Articles for PubMed (Select 14511401)

2.

In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.

Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, Waltenberger J, Thorpe P, Rosenblum MG.

Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7866-71. Erratum in: Proc Natl Acad Sci U S A 2002 Aug 6;99(16):10941.

3.

Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer.

Hotz HG, Gill PS, Masood R, Hotz B, Buhr HJ, Foitzik T, Hines OJ, Reber HA.

J Gastrointest Surg. 2002 Mar-Apr;6(2):159-66; discussion 166.

PMID:
11992800
4.

Cell surface tumor endothelial markers are conserved in mice and humans.

Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St Croix B.

Cancer Res. 2001 Sep 15;61(18):6649-55.

6.

Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.

Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE.

Cancer Res. 2000 Sep 15;60(18):5117-24.

7.

Tumor infarction by targeting tissue factor to tumor vasculature.

Thorpe PE, Ran S.

Cancer J. 2000 May;6 Suppl 3:S237-44. Review. No abstract available.

PMID:
10874493
8.

The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1.

Fuh G, Garcia KC, de Vos AM.

J Biol Chem. 2000 Sep 1;275(35):26690-5.

9.

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.

Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS.

J Clin Invest. 2000 Apr;105(8):R15-24. Erratum in: J Clin Invest. 2006 Nov;116(11):3084. J Clin Invest. 2006 Oct;116(10):2827.

10.

Tumor angiogenesis: past, present and the near future.

Kerbel RS.

Carcinogenesis. 2000 Mar;21(3):505-15. Review.

11.

Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.

Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ.

Cancer Res. 1999 Oct 15;59(20):5209-18.

12.

Expression of soluble VEGF receptor 2 and characterization of its binding by surface plasmon resonance.

Huang X, Gottstein C, Brekken RA, Thorpe PE.

Biochem Biophys Res Commun. 1998 Nov 27;252(3):643-8.

PMID:
9837760
13.

Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature.

Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE.

Cancer Res. 1998 Oct 15;58(20):4646-53.

14.

Host microvasculature influence on tumor vascular morphology and endothelial gene expression.

Roberts WG, Delaat J, Nagane M, Huang S, Cavenee WK, Palade GE.

Am J Pathol. 1998 Oct;153(4):1239-48.

15.

Vascular endothelial growth factor as a marker of tumor endothelium.

Brekken RA, Huang X, King SW, Thorpe PE.

Cancer Res. 1998 May 1;58(9):1952-9.

16.

Novel antibodies directed against the extracellular domain of the human VEGF-receptor type II.

Menrad A, Thierauch KH, Martiny-Baron G, Siemeister G, Schirner M, Schneider MR.

Hybridoma. 1997 Oct;16(5):465-71.

PMID:
9388030
17.
18.

Apoptotic vascular endothelial cells become procoagulant.

Bombeli T, Karsan A, Tait JF, Harlan JM.

Blood. 1997 Apr 1;89(7):2429-42.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk